(Total Views: 267)
Posted On: 07/19/2022 8:19:59 AM
Post# of 46
Will Aldeyra Hit the Bull’s Eye in Dry Eye?
$ALDX
Excited to share our latest coverage on Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) which announced positive results from the Phase 3 tranquility trial. The Company is scheduled to meet the FDA for a Type B Pre-NDA meeting in Q3, 2022, with a potential NDA submission likely to follow.
Read on to know more:
https://www.aviseanalytics.com/will-aldeyra-h...n-dry-eye/
$ALDX
Excited to share our latest coverage on Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) which announced positive results from the Phase 3 tranquility trial. The Company is scheduled to meet the FDA for a Type B Pre-NDA meeting in Q3, 2022, with a potential NDA submission likely to follow.
Read on to know more:
https://www.aviseanalytics.com/will-aldeyra-h...n-dry-eye/
(0)
(0)Scroll down for more posts ▼
